Global Custom Market Research Reports Provider Company

phone

United Kingdom Neurostimulation Devices Market Outlook to 2023

  • Published Date: 01 Jan 2017
  • Number of Pages: 92
  • Category: Healthcare and Medical
  • Country: United Kingdom
United Kingdom Neurostimulation Devices Market Outlook to 2023

Summary

GlobalDatas new report, "United Kingdom Neurostimulation Devices Market Outlook to 2023", provides key market data on the United Kingdom Neurostimulation Devices market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments - Cortical Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Spinal Cord Stimulators, Vagus Nerve Stimulators.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size and company share data for Neurostimulation Devices market segments - Cortical Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Spinal Cord Stimulators, Vagus Nerve Stimulators.
- Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
- 2016 company shares and distribution shares data for each of the market segments.
- Global corporate-level profiles of key companies operating within the United Kingdom Neurostimulation Devices market.
- Key players covered include Medtronic plc, Boston Scientific Corp, St. Jude Medical LLC and Others.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and whats the most preferred mode of product distribution - Identify, understand and capitalize.
Publisher Name : GlobalData
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 4
2 Introduction 5
2.1 What Is This Report About? 5
2.2 Neurostimulation Devices Market Segmentation 5
2.3 Definitions of Markets Covered in the Report 6
3 Neurostimulation Devices Market, United Kingdom 7
3.1 Neurostimulation Devices Market, United Kingdom, Revenue ($m), 2009-2016 7
3.2 Neurostimulation Devices Market, United Kingdom, Revenue ($m), 2016-2023 9
3.3 Neurostimulation Devices Market, United Kingdom, Volume (Units), 2009-2016 11
3.4 Neurostimulation Devices Market, United Kingdom, Volume (Units), 2016-2023 13
3.5 Neurostimulation Devices Market, United Kingdom, Average Price ($), 2009-2023 15
3.6 Neurostimulation Devices Market, United Kingdom, Distribution Share by Revenue ($m), 2015-2016 17
3.7 Neurostimulation Devices Market, United Kingdom, Company Share by Revenue ($m), 2016 18
4 Overview of Key Companies in United Kingdom, Neurostimulation Devices Market 20
4.1 Medtronic Plc 20
4.1.1 Company Overview 20
4.2 St. Jude Medical LLC 20
4.2.1 Company Overview 20
4.3 LivaNova PLC 20
4.3.1 Company Overview 20
4.4 Boston Scientific Corp 21
4.4.1 Company Overview 21
4.5 Integra LifeSciences Holdings Corp 21
4.5.1 Company Overview 21
5 Neurostimulation Devices Market Pipeline Products 22
6 Financial Deals Landscape 26
6.1 Acquisition 26
6.1.1 Nestle Health Science to Acquire Phagenesis 26
7 Recent Developments 27
7.1 Corporate Communications 27
7.1.1 Mar 31, 2017: LivaNova Announces Chief Financial Officer Resignation 27
7.1.2 Feb 01, 2017: Sanofi Appoints Hugo Fry as General Manager UK 27
7.1.3 Jan 19, 2017: Abbas Hussain to leave GSK 27
7.1.4 Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK 28
7.1.5 Dec 19, 2016: GSK announces Board changes 28
7.1.6 Nov 02, 2016: LivaNova Announces CEO Transition: Damien McDonald to Succeed Andre-Michel Ballester 29
7.1.7 Oct 14, 2016: AorTech International Announces Board Changes 29
7.1.8 Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare 30
7.1.9 Sep 20, 2016: Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline 30
7.1.10 Aug 01, 2016: LivaNova Names Chief Operating Officer 30
7.1.11 Jul 28, 2016: LivaNova Names Andrea L. Saia to its Board of Directors 31
7.1.12 Jul 07, 2016: GSK and Save the Children call for developing country innovations to enter $1 million award 32
7.1.13 Jun 14, 2016: GlaxoSmithKline: Executive Director Change 32
7.1.14 May 27, 2016: GlaxoSmithKline Announces Board and Committee changes 32
7.2 Financial Announcements 33
7.2.1 May 03, 2017: LivaNova Reports First Quarter 2017 Results 33
7.2.2 Apr 26, 2017: GSK delivers another quarter of continued progress 34
7.2.3 Mar 31, 2017: LivaNova Reiterates Full-Year 2017 Guidance 36
7.2.4 Mar 01, 2017: LivaNova Reports Fourth Quarter and Full-Year 2016 Results 36
7.2.5 Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016 38
7.2.6 Dec 21, 2016: AorTech International: Unaudited Interim Results For the six months ended 30 September 2016 52
7.2.7 Nov 02, 2016: LivaNova Reports Third Quarter 2016 Results 53
7.2.8 Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016 54
7.2.9 Sep 29, 2016: LivaNova Announces Half-Year Financial Report 59
7.2.10 Aug 15, 2016: AorTech International: Audited results for the year ended 31 March 2016 66
7.2.11 Aug 03, 2016: LivaNova Reports Second Quarter 2016 Results 68
7.2.12 Jul 27, 2016: GlaxoSmithKline: Results announcement for the second quarter 2016 and half-yearly financial report for the half-year 2016 69
7.3 Legal And Regulatory 83
7.3.1 Feb 23, 2017: LivaNova Announces Its Intent to Delist from London Stock Exchange 83
7.3.2 Dec 21, 2016: AorTech Shares Dive As Losses And Lawsuit Against Former CEO Continue 83
7.4 Other Significant Developments 83
7.4.1 Dec 13, 2016: Magstim announces new distribution partnership in Netherlands 83
7.4.2 Nov 15, 2016: CEVA to work with Medtronic for distribution facility construction 84
7.4.3 Jul 27, 2016: GSK announces significant new investment in UK manufacturing network 85
7.5 Strategy And Business Planning 85
7.5.1 Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms 85
7.5.2 Jul 06, 2016: LivaNova Sets Operating Model and Supporting Organization 86
7.5.3 May 20, 2016: Avalon Ventures and COI Pharmaceuticals Announce First Milestones for Sitari Pharmaceuticals and Silarus Therapeutics and Formation of Eighth Company 86
8 Appendix 88
8.1 Research Methodology 89
8.1.1 Coverage 89
8.1.2 Secondary Research 89
8.1.3 Primary Research 90
8.1.4 Company Share Analysis 90
8.1.5 Distribution Share Analysis 90
8.1.6 Benchmarking 91
8.2 GlobalData Consulting 91
8.3 Contact Us 92
8.4 Disclaimer 92

List Of Tables


Table 1: Neurostimulation Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 8
Table 2: Neurostimulation Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 10
Table 3: Neurostimulation Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 12
Table 4: Neurostimulation Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 14
Table 5: Neurostimulation Devices Market, United Kingdom, Average Price ($), Historic, 2009-2016 15
Table 6: Neurostimulation Devices Market, United Kingdom, Average Price ($), Forecast, 2016-2023 16
Table 7: Neurostimulation Devices Market, United Kingdom, Distribution Share by Revenue ($m), USD Constant, 2015-2016 17
Table 8: Neurostimulation Devices Market, United Kingdom, Company Share by Revenue ($m), USD Constant, 2016 19
Table 9: Neurostimulation Devices Market Pipeline Products 22
Table 10: Nestle Health Science to Acquire Phagenesis 26

List Of Figures


Figure 1: Neurostimulation Devices Market, United Kingdom, Revenue ($m), USD Constant, Historic, 2009-2016 7
Figure 2: Neurostimulation Devices Market, United Kingdom, Revenue ($m), USD Constant, Forecast, 2016-2023 9
Figure 3: Neurostimulation Devices Market, United Kingdom, Volume (Units), Historic, 2009-2016 11
Figure 4: Neurostimulation Devices Market, United Kingdom, Volume (Units), Forecast, 2016-2023 13
Figure 5: Neurostimulation Devices Market, United Kingdom, Company Share (%) 2016 18

In this report, the United States Medical Foods market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

View Report

In this report, the United States Firefighting Foam market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

View Report

In this report, the United States Displacement Sensor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports